T. Rowe Price Associates
TXMD icon

T. Rowe Price Associates’s TherapeuticsMD TXMD Stock Holding History

T. Rowe Price Associates’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,308
Closed -$234K – 3016
2022
Q1 		$234K Sell
12,308
-688
-5% -$10.8K ﹤0.01% 2655
2021
Q4 		$231K Buy
12,996
+10,352
+392% +$310K ﹤0.01% 2706
2021
Q3 		$98K Sell
2,644
-367,221
-99% -$16.3M ﹤0.01% 2853
2021
Q2 		$22M Buy
369,865
+3,605
+1% +$218K ﹤0.01% 1278
2021
Q1 		$24.5M Sell
366,260
-11,124
-3% -$871K ﹤0.01% 1222
2020
Q4 		$22.8M Sell
377,384
-3,772
-1% -$258K ﹤0.01% 1195
2020
Q3 		$30.1M Sell
381,156
-2,282
-0.6% -$182K ﹤0.01% 1038
2020
Q2 		$24M Sell
383,438
-3,773
-1% -$220K ﹤0.01% 1097
2020
Q1 		$20.5M Buy
387,211
+2,420
+0.6% +$240K ﹤0.01% 1070
2019
Q4 		$46.6M Buy
384,791
+78,711
+26% +$11.3M 0.01% 937
2019
Q3 		$55.6M Sell
306,080
-133,399
-30% -$18.8M 0.01% 835
2019
Q2 		$57.1M Sell
439,479
-562
-0.1% -$101K 0.01% 834
2019
Q1 		$107M Buy
440,041
+9,594
+2% +$2.54M 0.02% 618
2018
Q4 		$82M Sell
430,447
-75,942
-15% -$18.5M 0.01% 655
2018
Q3 		$166M Buy
506,389
+38,303
+8% +$11.7M 0.02% 533
2018
Q2 		$146M Buy
468,086
+127,838
+38% +$39.1M 0.02% 559
2018
Q1 		$82.8M Sell
340,248
-8,380
-2% -$2.35M 0.01% 694
2017
Q4 		$105M Buy
348,628
+35,848
+11% +$9.98M 0.02% 623
2017
Q3 		$82.7M Sell
312,780
-87,723
-22% -$25.4M 0.01% 679
2017
Q2 		$106M Sell
400,503
-110,943
-22% -$27.8M 0.02% 582
2017
Q1 		$184M Buy
511,446
+38,182
+8% +$11.8M 0.03% 441
2016
Q4 		$137M Buy
473,264
+3,955
+0.8% +$1.23M 0.03% 514
2016
Q3 		$160M Buy
469,309
+35,966
+8% +$13.1M 0.03% 474
2016
Q2 		$184M Buy
433,343
+14,815
+4% +$6.11M 0.04% 434
2016
Q1 		$134M Buy
418,528
+209,649
+100% +$71.5M 0.03% 473
2015
Q4 		$108M Buy
208,879
+60,164
+40% +$22.2M 0.02% 537
2015
Q3 		$43.6M Buy
148,715
+57,186
+62% +$20.3M 0.01% 813
2015
Q2 		$36M Buy
91,529
+13,586
+17% +$4.79M 0.01% 950
2015
Q1 		$23.6M Buy
+77,943
New +$19M ﹤0.01% 1076

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

T. Rowe Price Associates's TXMD Position: Q2 2022 in Review

T. Rowe Price Associates sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 12,308 shares — an estimated $234K sold.

T. Rowe Price Associates first reported a position in TXMD in Q1 2015 and held it in 29 quarters. The position peaked at $184M in Q2 2016. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • T. Rowe Price Associates reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 12,308 TherapeuticsMD shares in Q2 2022, an estimated $234K.
  • T. Rowe Price Associates first reported a position in TherapeuticsMD in Q1 2015 and held it in 29 quarters.
  • T. Rowe Price Associates's TherapeuticsMD position peaked at $184M in Q2 2016.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.